Obesity drug significantly reduces the risk of infections and serious cardiovascular events
Tirzepatide, marketed under the brand name Mounjaro, could reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes by by about one-third when compared with a conventional diabetes medication.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.